Speakers
Agnieszka Denslow
Associate Director
Pharmacology / Toxicology, Oncorus
Day Two
Thursday, July 14, 2022
8:30 am | Modelling Small Cell Lung Cancer in Preclinical Development of Synthetic Oncolytic Virus
Andrew Puca
Director, Corporate & Commercial Development
The Jackson Laboratory
Day One
Wednesday, July 13, 2022
9:30 am | Leveraging the Power of Novel Humanized Models to Support Preclinical Oncology Studies in the Context of Changing FDA Pre-IND Requirements
Anita Seshire
Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology
EMD Serono
Day One
Wednesday, July 13, 2022
4:20 pm | Developing Clinically Translatable Models that Accurately Represent Patient Metastasis
Beatrice Wang
Associate Director
IGM Biosciences
Day One
Wednesday, July 13, 2022
8:00 am | Combination of a Multimeric Anti-DR5 IgM Antibody with Targeted Agents Induces Synergistic Tumor Cytotoxicity in Vitro & in Vivo
David Draper
Associate Director, Scientific Development
Labcorp
Day One
Wednesday, July 13, 2022
3:15 pm | Session Reserved for Labcorp
Douglas Palmer
Executive Director of Immuno-Oncology Translational Medicine
AstraZeneca
Translation Track - Day 1 am
12:45 pm | Roundtable Discussion: Right Tumor, Right Model, Wrong Drug
Douglas Powell
Director, Scientific Engagement
Crown Bioscience
Day One
Wednesday, July 13, 2022
8:30 am | Leveraging PDX-derived Organoid (PDXO) Models for Combination Targeted Oncology
Eric Ibsen
Chief Executive Officer
Studylog
Esmaiel Jabarri
Professor
University of South Carolina
Day Two
Thursday, July 14, 2022
2:45 pm | 3D Screening Model for Combination Drugs Against Tumor Differentiated & Undifferentiated Cells
Frank Sun
Senior Principal Scientist, Oncology Pharmacology
Sanofi
Preclinical Track - Day 1 am
11:45 am | Humanized Mouse Model as a Translational Tool for Immunotherapy in Oncology
Gareth Griffiths
CSO
Imagen Therapeutics
Day One
Wednesday, July 13, 2022
10:00 am | Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle
Javier Pineda
Bioinformatics Lead
Scientist.com
Day Two
Thursday, July 14, 2022
12:00 pm | The Disease Model Finder: An AI-Powered Platform to Enhance Disease Model Sourcing
Jean Viallet, PhD.
CEO/CSO
Inovotion
Day Two
Thursday, July 14, 2022
10:45 am | Combination Approach: Using Chicken Egg In vivo assay for High-Value Identification of Oncology and Immuno-Oncology drugs Candidates
Jenna Frame
PhD, Sr. Manager, Scientific Communications & Marketing
Biocytogen
Day One
Wednesday, July 13, 2022
4:50 pm | Preclinical Evaluation of Novel Combination Therapies Using Multigenic Humanized Models
Jessica Haverkamp
Associate Director Macrophage Biology
BlueRock Therapeutics
Day One
Wednesday, July 13, 2022
5:20 pm | Chair’s Closing Remarks & End of Conference Day One
7:50 am | Chair’s Opening Remarks
Preclinical Track - Day 1 am
11:15 am | Fireside chat: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification
Jingjing Jiang
Senior Director, Translational Research
Revolution Medicines
Translation Track - Day 1 am
11:45 am | Combination Therapy to Outsmart RASAddicted Cancer - Informing Clinical Strategy with Preclinical Modeling
Johanna K. Kaufmann
EVP Oncology
Codagenix
Johanna Lahdenranta
Director In Vivo Pharmacology
Bicycle Therapeutics
Translation Track - Day 1 am
12:15 pm | Exploring Tumor Localized CD137 Agonism with Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICAs®)
Juan Arriaga
Assistant Professor – Department of Oncological Sciences & Urology
Icahn School of Medicine at Mount Sinai
Day One
Wednesday, July 13, 2022
2:45 pm | Modeling Bone Metastasis of Prostate Cancer
Day Two
Thursday, July 14, 2022
3:45 pm | Panel Discussion - What Are the Advantages of 3D Models
Julie Gerardi
VP, Viological Modeling & Functional Genomics Business Development
Tempus
Day Two
Thursday, July 14, 2022
9:00 am | Applying Real-World Data & Tumor Modeling to Discovery & Translational Research
Jun Zhang
MD, PhD, Associate Professor
University of Kansas Medical Center, Medical Oncology
Kader Thiam
SVP Discovery - Preclinical Models & Services
Genoway
Day One
Wednesday, July 13, 2022
2:15 pm | Precise and translational preclinical models for assessment of immune-targeting agents
Katie Grausam
Postdoctoral Scientist
Cedars Sinai
Day Two
Thursday, July 14, 2022
11:15 am | Weighing up Pros & Cons of Quick & Dirty Models Versus Slower Growing Models
3:45 pm | Panel Discussion - What Are the Advantages of 3D Models
Khalid Shah
Vice Chairman at BWH
Harvard Medical School
Day One
Wednesday, July 13, 2022
9:00 am | Translatability at a Glance: Combined Gene Edited & Engineered Cellular Therapies for Solid Tumors
Kimberly Aardalen
Scientific Technical Leader
Novartis Institutes for Biomedical Research
Ludovic Bigot
Project Manager
Gustav Rousey
Day Two
Thursday, July 14, 2022
2:15 pm | MATCH-R: A Preclinical Platform of Resistant Models to Innovative Therapies • Highlighting the development of a panel
Marc Pelletier
Senior Principal Scientist
Novartis
Preclinical Track - Day 1 am
11:15 am | Fireside chat: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification
Marc Zuckermann
Group Leader Preclinical Modeling
German Cancer Research Center (DKFZ)
Translation Track - Day 1 am
11:15 am | Targeting c-MET in Combination with Radiation is Effective in MET-Fusion Driven High- Grade Glioma
Marco Campisi
Postdoctoral Research Fellow
Dana-Farber Cancer Institute
Day Two
Thursday, July 14, 2022
3:45 pm | Panel Discussion - What Are the Advantages of 3D Models
1:15 pm | Retaining the Tumor Immune Microenvironment Heterogeneity & Vascular Cross-talks in Ex-Vivo Microphysiological Models
Mark Moore PhD
CEO
GemPharmatech
Day One
Wednesday, July 13, 2022
3:50 pm | Accelerating Antibody Research Using Humanized Mouse Models
Matthew Hebb
Neurosurgeon Scientist
University of Western Ontario
Day Two
Thursday, July 14, 2022
11:45 am | Orthotopic & Metastatic Xenograft Studies in the SRG Rat
Monika Buczek
PhD, Director of Business Development
Business Development
Day Two
Thursday, July 14, 2022
10:00 am | Translating Preclinical Combinatorial Therapy Approaches in In Vitro & In Vivo Models of Human Glioblastoma Multiforme
Natalia Blanco
Associate Director, Immuno-Oncology
Morphic Therapeutic
Preclinical Track - Day 1 am
12:30 pm | Treatment Modalities to Improve Response in Tumors Refractory to Standard Immunotherapy Approaches
Scott Boiko
Associate Director Translational Science
Forma Therapeutics
Day Two
Thursday, July 14, 2022
9:15 am | Roundtable: Outlining Model Validation & Establishing the Need for Standardization
4:45 pm | Chair’s Closing Remarks & End Of Summit
8:20 am | Chair’s Opening Remarks
Senior Representative
Hera BioLabs
Shiva Kazerounian
Associate Director of in Vivo Pharmacology
Berg Health
Soner Altiok
CSO
Nilogen Oncosystems
Tessa DesRochers
Chief Scientific Officer
Kiyatec Inc
Preclinical Track - Day 1 am
12:15 pm | De-Risking Drug Development by Incorporating Clinically Correlated Ex Vivo Models
Thomas Schürpf
Senior Director, Tumor Biology
Parthenon Therapeutics
Day Two
Thursday, July 14, 2022
4:15 pm | Breaking Down Barriers In Immune-Excluded Tumor Biology
Tomasz Owczarek
Senior Staff Scientist
Regeneron
Day Two
Thursday, July 14, 2022
1:45 pm | Model Selection for Tumor Heterogeneity & TME
William Coward
Business Development Manager
Nilogen Oncosystems